Telegraph

7x24 real-time news feed, auto refreshBeijing Time：

🔄 Auto refresh 🔔 Sound 💬 Notify

All A·Important B·Normal #细胞 ✕

[AI pharmaceuticals and CRO concepts pick up in the afternoon, Berry Genetics 6 days and 3 boards] On October 9th, AI pharmaceuticals and CRO concepts picked up in the afternoon, Berry Genes went straight up to the daily limit, out of 6 days and 3 boards, Technomax rose by more than 10%, Jinshi Yaoyao, Tuojing Life, InnoCare, Shenzhou Cells, etc. quickly surged higher. According to the news, Isomorphic Labs, an AI drug research and development start-up, is advancing preliminary negotiations for a new round of financing. The post-investment valuation of this round is at least US$40 billion, and is expected to reach a maximum of US$50 billion.

#drug research and development #Phi #Gene #cell #Live broadcast #AI medical10-09 14:04

[Alice: The phase III clinical trial of fumetinib did not meet the primary study endpoint] On October 7, Ellis (688578.SH) announced that the company's product fumetinib mesylate tablets ("vometinib") monotherapy is FURVENT for the treatment of previously untreated patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. The Phase III trial did not meet its primary endpoint of progression-free survival (PFS) as assessed by blinded independent central review (BICR). Clinical benefit was observed on secondary endpoints such as investigator-assessed PFS and BICR-assessed confirmed objective response rate (ORR); although overall survival (OS) data are not yet mature, a clear trend of improvement has been observed. The safety profile observed in the FURVENT trial was consistent with previous clinical studies of fumetinib, and no new safety signals were found. Together with ArriVent, the company is evaluating FURVENT's complete data set to determine next steps. As of September 30, 2026, the company has invested a total of approximately 70.82 million yuan in key clinical trials of fumetinib for first-line treatment of exon 20 insertion mutations. The above-mentioned research and development expenses have been included in the profits and losses of the corresponding accounting period when they are incurred, and will not have a significant impact on the company's current performance.

#clinical trial #cell #A-share announcement express10-07 16:28

[Betta Pharmaceuticals: BPI-572270 capsules have been approved by the U.S. FDA for clinical trials of new drugs] On October 7, Betta Pharmaceuticals (300558.SZ) announced that the clinical trial application for BPI-572270 capsules submitted by the company's wholly-owned subsidiary Jingyao Biotech was approved by the U.S. FDA and is intended to be used for advanced solid tumors. The drug is a self-developed pan-RAS "non-degradable molecular glue" inhibitor. Preclinical studies have shown that it has a strong inhibitory effect on a variety of RAS mutated tumor cells. The company reminds that the research and development cycle of new drugs is long, the investment is large, and the results of clinical trials and approvals are uncertain, which will not have a significant impact on recent performance.

#clinical trial #molecular #cell #A-share announcement express10-07 16:16

[For the first time in the world, a Chinese team constructed a three-dimensional spatio-temporal cell map of the entire rice life cycle] On October 7, the reporter learned from the Yazhou Bay National Laboratory that the latest rice research results, completed by the collaboration of multiple scientific research institutions in China, were published online in the international academic journal Cell on the evening of the 6th. The content is that a Chinese research team has constructed for the first time in the world a three-dimensional spatio-temporal cell map covering the entire process of rice from seed germination to flowering and fruiting. It integrates genome sequencing, single-cell sequencing and spatial transcriptome sequencing, providing new research resources for understanding rice growth and development and exploring grain quality improvement. (CCTV News)

#genome #Gene #cell #research #agricultural planting10-07 09:28

[Chinese researchers decipher the "bacterial code" of migratory locusts gathering to lay eggs] On October 2, we learned from the Institute of Agricultural Genomics, Chinese Academy of Agricultural Sciences, that recently, the Agricultural Pest Genomics Innovation Team of the Institute of Agricultural Genomics, Chinese Academy of Agricultural Sciences, in conjunction with many scientific research units at home and abroad, revealed the molecular mechanism by which migratory locusts gather and lay eggs with the help of maternally transmitted symbiotic bacteria. Relevant research results were published in Cell.

#genome #molecular #Gene #cell #research #bacteria10-02 11:55

[CanSino: It is developing mRNA preventive vaccines and therapeutic biological products, as well as the development of related delivery systems] On September 30, CanSino (688185.SH) issued an announcement of abnormal stock trading fluctuations. The company is concerned about the recent development of mRNA technology in the market, and overseas clinical phase data of mRNA tumor vaccines have been released or planned to be made public. The mRNA platform is one of the technology platforms deployed by the company. The company is developing mRNA preventive vaccines and therapeutic biological products, as well as related delivery systems. In terms of therapeutic areas, the company is advancing the research and development of mRNA vaccines for the treatment of indications such as glioblastoma, rhabdomyosarcoma and cervical cancer, as well as the development of InVivoCAR-related therapies, which are currently in early stages.

#vivo #RNA #cell #vaccine #A-share announcement express #A-share risk warning announcement09-30 18:48

[AI identifies the aging state of hematopoietic stem cells with an accuracy of 77%] September 30th, whether cells are old or not may be hidden in subtle changes in the cell nucleus. Scientists from Spain's Belvite Biomedical Research Institute and other institutions have developed an artificial intelligence (AI) tool that can identify these changes in three-dimensional microscopic images of hematopoietic stem cell nuclei and distinguish young cells from senescent cells with 77% accuracy. This provides new technical means for studying blood stem cell aging and finding ways to intervene in cell aging. Relevant research was published in the journal "Senescent Cells" on the 28th.

#AI #stem cells #medicine #cell #Global market intelligence09-30 06:57

[Functional map of genes regulating changes in human bones released] On September 28, institutions such as the Institute of Advanced Human Biology at Kyoto University in Japan released the first functional map of the "human bone gene switch" in the latest issue of "Nature". This study combines whole-genome alignment, massively parallel reporter analysis of chondrocytes, and "human-great ape hybrid cells" to show that cartilage maintenance molecules glycosaminoglycans (GAGs) have been significantly reduced during human evolution, providing evidence for understanding bone formation and why humans are more susceptible to osteoarthritis.

#biology #genome #molecular #Gene #cell #Global market intelligence09-28 07:15

[Four-connected Nanhua Bio: Cell therapy-related technologies and products are still in the research and development stage, and no innovative drugs have been launched or entered the clinical trial stage] On September 22, Nanhua Bio (000504.SZ) issued a stock trading risk warning announcement stating that the company's current main business is biomedicine and energy conservation and environmental protection. Among them, the biomedicine segment mainly provides customers with testing and storage services for biological resources such as stem cells and immune cells. It also cooperates with a number of clinical research institutions to provide them with cell preparation, testing and other services that meet clinical research requirements. The company's cell therapy-related technologies and products are still in the research and development stage, and no innovative drugs have been launched or entered the clinical trial stage. The energy-saving and environmental protection segment is mainly engaged in lithium carbonate business, scrap steel renewable resources and supporting processing and sales.

#clinical trial #stem cells #cell #A-share announcement express #A-share risk warning announcement09-22 18:20

[Yahong Pharmaceutical: APL-2501 has completed the enrollment of the first subject in the Phase I clinical trial] On September 22, Yahong Pharmaceutical (688176.SH) announced that the company's independently developed APL-2501 has completed the enrollment of the first subject in the Phase I/II clinical trial in patients with advanced solid tumors. The drug is an anti-CLDN6/9 antibody-drug conjugate independently developed by the company based on a topoisomerase inhibitor. It can be used to treat a variety of advanced solid tumors such as ovarian cancer, non-small cell lung cancer, endometrial cancer, and gastric cancer. The research has been approved by the US FDA and the State Food and Drug Administration, and this matter will not have a significant impact on the company's recent performance.

#clinical trial #cell #A-share announcement express09-22 17:43

[Lukang Pharmaceutical: Obtained registration approval for imatinib mesylate tablets and API] On September 22, Lukang Pharmaceutical (600789.SH) announced that the company recently received the "Drug Registration Certificate" for imatinib mesylate tablets and the "Chemical API Marketing Application Approval Notice" for imatinib mesylate API issued by the State Food and Drug Administration. This drug is a protein tyrosine kinase inhibitor and is used to treat chronic myelogenous leukemia, etc. This approval enriches the company's product line of preparations and APIs and helps enhance market competitiveness.

#Chemical #cell #A-share announcement express09-22 16:24

["Prime assembly" can accurately stitch long DNA fragments] On September 21, a research team from Boston Children's Hospital in the United States published a new genome editing method called "prime assembly" in the latest issue of "Nature" magazine. This technology can precisely "stitch" long DNA fragments to precise programmable sites in the genome of living cells, and repair multiple mutations simultaneously in one operation. This advance could lead to the development of universal gene therapies suitable for most patients.

#gene therapy #DNA #genome #programming #Gene #cell #Global market intelligence09-21 06:37

[Betta Pharmaceuticals: Ensartinib Hydrochloride Capsules received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency] On September 20, Beida Pharmaceutical (300558.SZ) announced that the marketing authorization application for ensartinib hydrochloride capsules submitted by the company’s holding subsidiary The European Commission will make a final decision based on this positive opinion, and there is still uncertainty about whether the marketing authorization application can be approved. Ensartinib is a new generation ALK inhibitor that has been approved for marketing in China, the United States and Macau.

#cell #A-share announcement express09-20 16:15

[Merck’s new formulation of Premin® Letermovir Tablets (II) is launched in China] On September 16, Merck announced that its new non-nucleoside cytomegalovirus (CMV) inhibitor Premin®’s new dosage form Letermovir Tablets (II) has been officially launched in China It is marketed in China for the prevention of cytomegalovirus infection and cytomegalovirus disease in adults and pediatric recipients 6 months and older and weighing ≥6kg who are seropositive for cytomegalovirus (CMV) who have received allogeneic hematopoietic stem cell transplantation (HSCT) [R+].

#stem cells #Gene #cell #Virus #medicine09-16 17:06

[AI Model Discovers "Invisible" Protein TM184C in Human Body] On September 16th, American scientists published a paper in the latest issue of "Nature" magazine saying that with the help of artificial intelligence (AI) model, they discovered the "invisible" protein in human body and revealed its true purpose. This opens up new ideas for understanding how cells "communicate", survive under stress, and how disease develops.

#AI #protein #cell #Global market intelligence09-16 07:09

[CSPC Innovation: SYS6010 included in the list of breakthrough therapies] On September 15th, CSPC Innovation (300765.SZ) announced that SYS6010, developed by the company's holding subsidiary Jushi Biologics, was included in the list of breakthrough therapies by the Drug Evaluation Center of the State Food and Drug Administration. The proposed indication is recurrent or metastatic driver gene-negative non-squamous non-small cell lung cancer that has failed immune and platinum-containing chemotherapy. SYS6010 is an antibody conjugate drug targeting EGFR, and its Phase III clinical trials are currently underway. The drug has previously received three breakthrough therapy designations.

#clinical trial #Gene #cell #A-share announcement express09-15 16:32

[Baitu Biotech and MGI reach strategic cooperation Jointly build an exclusive large-scale cell model] September 14th, according to MGI news, on September 11, Baitu Biotechnology (Beijing) Intelligent Technology Co., Ltd. (referred to as "Baitu Biotechnology") announced the formal signing of a strategic cooperation agreement with MGI. The two parties will jointly target specific customers and research and development scenarios. We will jointly build an exclusive large-scale cell model, focusing on improving capabilities such as cell state modeling and disturbance response prediction. We will use this as a base to build an exclusive high-quality data infrastructure for virtual cells and virtual disturbances, explore integrated product models such as "device + model + agent", and accelerate the AI4S process.

#agent #large model #cell #Futures Market Intelligence #AI09-14 11:38

[Research shows that three-dimensional tumor models can help speed up the development of anti-cancer drugs] On September 13, researchers from the University of Manchester in the UK recently published a paper in the British Journal of Cancer saying that using biomaterials to construct a three-dimensional tumor model in the laboratory that is close to the real tumor environment of the human body can help speed up the development of anti-cancer drugs. According to a press release issued by the University of Manchester, researchers analyzed cancer tumor models based on advanced biomaterials such as hydrogels. This type of material can serve as a scaffold for cells to attach and grow. By adding various cells to the three-dimensional structure formed by it, a miniature "tumor ecosystem" can be constructed, which can be used to simulate and analyze characteristics such as cell-cell interactions and drug resistance. Researchers pointed out that in the past, flat materials were often used when cultivating cancer cells, which was difficult to simulate the complex environment and cell interactions inside real tumors. Therefore, some drug candidates that performed well in tests may not be effective in subsequent stages. Three-dimensional tumor models can provide a drug testing environment that is closer to the actual situation in the human body and help screen more potential drug candidates.

#ecosystem #drug research and development #cell #AI09-13 12:13

[Shanghai Proof-of-Concept Platform Alliance Established] On September 12th, during the Science and Industry Integration Ecological Seminar of the 2026 Pujiang Innovation Forum Results Release held on September 12, the Shanghai Proof-of-Concept Platform Alliance was officially established. It was learned from the Shanghai Municipal Science and Technology Commission that the first batch of members of the alliance consists of 33 proof-of-concept platforms and future industry funds, covering future industrial fields such as brain-computer interfaces, silicon light, cell and gene therapy, as well as key industrial directions such as integrated circuits, intelligent manufacturing, and green technology. The alliance will promote the platform from "fighting independently" to "making a fist with fingers", focusing on capacity sorting, resource sharing, standard formulation, talent cultivation and other work, establishing a mutual recommendation and joint verification mechanism for projects, and accelerating the expansion of the platform matrix. (China Business News)

#brain computer interface #interface #Gene #cell #semiconductor chip #Smart manufacturing09-12 17:22

[Inner Mongolia: Accelerate the progress of African swine fever vaccine research and development] On September 11, the General Office of the People's Government of the Inner Mongolia Autonomous Region recently issued the "Action Plan for Accelerating the High-Quality Development of the Biomanufacturing Industry in the Inner Mongolia Autonomous Region." It is proposed to enhance the core competitiveness of biomedicine. Accelerate the establishment and operation of platforms such as the Hohhot Bio-Intelligent Manufacturing Valley, focus on nucleic acid drugs, cell and gene therapy, "AI + medicine" and other characteristic new tracks, and promote the biomedical industry to leapfrog from scale advantages to technology leadership. Consolidate and enhance the global market leading position of animal vaccine products such as foot-and-mouth disease vaccine, accelerate the research and development of African swine fever vaccines, strengthen the promotion and application of new vaccines and multi-linked multivalent vaccines in the region, and improve the prevention and control capabilities of major animal diseases. Leverage the platform advantages of the company's P3 laboratory to accelerate the development and industrialization of cutting-edge products such as mRNA vaccines and mucosal vaccines, and build a world-leading intelligent manufacturing benchmark for animal vaccines. Deepen the secondary development of traditional Chinese medicine (Mongolian medicine), use synthetic biology technology to enable the discovery and efficient preparation of functional components of characteristic Chinese medicine (Mongolian medicine), and create a modern traditional Chinese medicine (Mongolian medicine) industrial system with Inner Mongolian characteristics.

#Biotechnology #RNA #Gene #cell #animal #vaccine #modern #Futures Market Intelligence09-11 17:19

[Hengrui Pharmaceuticals: Ruikang totumumab for injection has been included in the list of breakthrough therapies] On September 11, Hengrui Medicine (600276.SH) announced that the company's subsidiary Suzhou Shengdia Biopharmaceutical Co., Ltd.'s Ruikang totumumab for injection has been included in the list of breakthrough therapies by the Drug Evaluation Center of the State Food and Drug Administration. The proposed indication is to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR mutations in combination with bevacizumab. This drug is an antibody-drug conjugate targeting HER3. There is no similar drug approved to treat NSCLC in the world, and the cumulative R&D investment in related projects is approximately 355 million yuan.

#cell #A-share announcement express09-11 16:50

[Shi4 Pharmaceutical Group: Letermovir Injection received drug production registration approval] On September 10th, Shi4 Pharmaceutical Group issued a voluntary announcement that the company has obtained the drug production registration approval document from the China National Medical Products Administration for Letermovir Injection (12ml:240mg). This product belongs to Category 4 chemical drugs and is deemed to have passed the consistency evaluation. Letermovir injection is mainly used for cytomegalovirus (CMV) seropositive adult recipients who have received allogeneic hematopoietic stem cell transplantation to prevent cytomegalovirus infection and cytomegalovirus disease. It needs to be used in combination with basic infusion and should be used in the perioperative period of hematopoietic stem cell transplantation. Relying on the existing advantages of basic infusion, the Group continues to improve the therapeutic injection product pipeline, and this approval further enriches the perioperative product portfolio.

#stem cells #Chemical #Gene #cell #Virus #generic drugs #chemicals #Hong Kong stock trends09-10 12:04

[Latest super large-scale study: Drinks that are too hot may significantly increase the risk of esophageal cancer] September 9th, one of the world’s largest related studies to date found that drinking tea and coffee that is too hot may significantly increase the risk of esophageal cancer. The world's largest study of its kind, led by the University of Oxford, based on a 14-year follow-up of nearly 980,000 people in the UK, found that drinking hot drinks at "very hot" temperatures will increase the risk of esophageal squamous cell cancer by about three times. Cancer experts say the findings suggest people should cool down scalding tea and coffee to a suitable drinking temperature to reduce the risk of esophageal cancer.

#cell #Food and Beverage #Agricultural products futures09-09 21:18

[Baili Tianheng: The first subject has been enrolled in the Phase III clinical trial of Yizekang] On September 9, Bailey Tianheng (688506.SH) announced that the company's independently developed world's first dual-antibody ADC Yizekang has completed the enrollment of the first subject in its Phase III clinical trial for the maintenance treatment of unresectable EGFR-mutated non-small cell lung cancer after concurrent radiotherapy and chemotherapy. Up to now, Yizekang has conducted more than 45 clinical trials in China and the United States, including 20 phase III clinical studies. Seven indications have been included in the list of breakthrough therapies by CDE, and two indications have been approved for marketing by NMPA.

#clinical trial #cell #A-share announcement express09-09 17:05

[Taenkang: The first subject has been enrolled in the phase IIb clinical trial of CKBA cream, an innovative drug for rosacea indications of its holding subsidiary] On September 7, Tynekang (301263.SZ) announced that the first subject was enrolled in the phase IIb clinical trial of CKBA cream, a Class 1 innovative drug for the treatment of rosacea, organized by Jiangsu Bochuangyuan Biomedical Technology Co., Ltd., the company’s holding subsidiary. This drug is the world's first innovative small molecule targeting the fatty acid metabolism pathway of T cells and has global independent intellectual property rights from China, the United States, the European Union and Japan. As of now, no Class 1 innovative drugs for the treatment of rosacea have been approved for marketing in China.

#clinical trial #molecular #cell #A-share announcement express09-07 20:32

[Merck’s PD-1 inhibitor Keytruda is approved for locally advanced head and neck squamous cell carcinoma in China] On September 4, Merck announced that its PD-1 inhibitor Keytruda® (pembrolizumab) has been approved by the China National Medical Products Administration (NMPA). Adult patients with surgically resectable locally advanced head and neck squamous cell carcinoma whose tumors were evaluated for PD-L1 expression (composite positive score (CPS) ≥1) were treated with single-agent neoadjuvant therapy, followed by adjuvant therapy with radiotherapy with or without cisplatin chemotherapy after surgery, and then continued pembrolizumab monotherapy.

#cell09-04 08:47

[Betta Pharmaceuticals: Ensartinib Hydrochloride Capsules received a drug registration certificate for postoperative adjuvant treatment indications] On September 3, Beida Pharmaceuticals (300558.SZ) announced that the company received a Drug Registration Certificate issued by the State Drug Administration for ensartinib hydrochloride capsules (trade name: Bemena) for postoperative adjuvant treatment of patients with ALK-positive stage IB to IIIB non-small cell lung cancer. This is the third approved indication for the drug. Ensartinib is a new generation of potent and highly selective ALK inhibitor. Its 2-year disease-free survival rate in postoperative adjuvant therapy reaches 86.4%, and the risk of recurrence is reduced by 80%. This approval will have a positive effect on the company's operating income.

#cell #A-share announcement express09-03 15:52

[Hidden immune cells in the lungs can prevent viruses from "taking root" in the respiratory tract] September 3rd, a new study conducted by a research team at the University of Rochester School of Medicine in the United States found that a previously ignored immune cell in the lungs can prevent viruses from "taking root" in the respiratory tract, thus helping to produce better flu vaccines. The relevant paper was published in the new issue of the journal Nature Immunology.

#Immunology #medicine #cell #Virus #vaccine #Global market intelligence09-03 07:04

[CSPC Innovation: SYS6010 included in the list of breakthrough therapies] On September 1, CSPC Innovation (300765.SZ) announced that SYS6010, developed by the company's holding subsidiary Jushi Biologics, was included in the list of breakthrough therapies by the Drug Evaluation Center of the State Food and Drug Administration. The proposed indication is for patients with recurrent or metastatic head and neck squamous cell carcinoma who have failed immune and platinum-containing chemotherapy. SYS6010 is an antibody-drug conjugate targeting EGFR, and key Phase III clinical trials for this indication are currently underway. Previously, SYS6010 has received two breakthrough therapy designations, respectively for EGFR mutation-positive advanced non-small cell lung cancer and advanced esophageal squamous cell carcinoma.

#clinical trial #cell #A-share announcement express09-01 16:56

[CAR-T therapy significantly reduces the symptoms of severe rheumatoid arthritis] September 1st, Chimeric Antigen Receptor T-cell immunotherapy (CAR-T) is mainly used to treat cancer, but this type of personalized therapy prepared from the patient's own immune cells is also expected to be used for autoimmune diseases. German scientists reported the results of the world's first relevant clinical trial: After receiving CAR-T treatment, the symptoms of six patients with severe rheumatoid arthritis were significantly reduced, and three of them no longer needed any anti-rheumatic drugs at the end of the observation period. The relevant paper was published in the latest issue of Nature Medicine.

#clinical trial #medicine #cell #Global market intelligence09-01 07:11